Ting Lee - Concord Medical Independent Non-Executive Director

CCM Stock  USD 0.57  0.01  1.71%   

Director

Mr. Ting Bun Lee, CPA, is Independent NonExecutive Director of Concord Medical Services Holding Ltd., since December 2009. Mr. Lee is currently a nonexecutive director of Netease.com, Inc., a company listed on the Nasdaq Global Select Market, and an independent director and chairman of the audit committee of three NYSE listed companies, New Oriental Education Technology Group Inc., Acorn International, Inc. and Gushan Environmental Energy Limited. Previously, Mr. Lee was the chief financial officer of Netease.com until June 2007 and the financial controller of Netease.com from November 2001 to April 2002. Prior to joining Netease.com in 2001, Mr. Lee worked in the Hong Kong office of KPMG for more than ten years. Mr. Lee graduated from the Hong Kong Polytechnic University majoring in accounting and is a member of The Hong Kong Institute of Certified Public Accountants and The Chartered Association of Certified Accountants. since 2009.
Age 51
Tenure 15 years
Address Tower A, Global Trade Center, Beijing, China, 100013
Phone86 10 5903 6688
Webhttps://www.concordmedical.com

Concord Medical Management Efficiency

The company has Return on Asset of (0.048) % which means that on every $100 spent on assets, it lost $0.048. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.2823) %, meaning that it generated no profit with money invested by stockholders. Concord Medical's management efficiency ratios could be used to measure how well Concord Medical manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of April 2024, Return On Equity is likely to grow to 0.18, while Return On Tangible Assets are likely to drop (0.06). At this time, Concord Medical's Other Current Assets are very stable compared to the past year. As of the 25th of April 2024, Intangible Assets is likely to grow to about 400.1 M, while Other Assets are likely to drop about 26.2 M.
The company has 3.25 B in debt with debt to equity (D/E) ratio of 1.25, which is OK given its current industry classification. Concord Medical Services has a current ratio of 0.7, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. Debt can assist Concord Medical until it has trouble settling it off, either with new capital or with free cash flow. So, Concord Medical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Concord Medical Services sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Concord to invest in growth at high rates of return. When we think about Concord Medical's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Parvinderjit KhanujaSelect Medical Holdings
62
John RuffleAmerican Shared Hospital
78
James ElySelect Medical Holdings
63
Bryan CresseySelect Medical Holdings
71
Andrew AdamsNational HealthCare
72
Richard KerleyThe Joint Corp
67
Lee DanielsThe Ensign Group
61
Barry SmithThe Ensign Group
64
Daren ShawThe Ensign Group
61
James DaltonSelect Medical Holdings
73
John MaupinEncompass Health Corp
73
Malene DavisThe Ensign Group
55
John NackelThe Ensign Group
66
Leslye KatzEncompass Health Corp
66
David LarsonAmerican Shared Hospital
78
Daniel ThomasSelect Medical Holdings
62
Marilyn TavennerSelect Medical Holdings
69
Emil HassanNational HealthCare
72
Steven ColmarThe Joint Corp
58
William FieldsThe Joint Corp
65
Sandra LawrenceAmerican Shared Hospital
61
Concord Medical Services Holdings Limited, together its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the Peoples Republic of China. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, the Peoples Republic of China. Concord Medical operates under Medical Care Facilities classification in the United States and is traded on New York Stock Exchange. It employs 972 people. Concord Medical Services (CCM) is traded on New York Stock Exchange in USA. It is located in Tower A, Global Trade Center, Beijing, China, 100013 and employs 727 people. Concord Medical is listed under Health Care Providers & Services category by Fama And French industry classification.

Management Performance

Concord Medical Services Leadership Team

Elected by the shareholders, the Concord Medical's board of directors comprises two types of representatives: Concord Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Concord. The board's role is to monitor Concord Medical's management team and ensure that shareholders' interests are well served. Concord Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Concord Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
Xun Liu, Financial Controller
Shangyan Chuang, Director
Matthew Callister, Chief Medical Officer
Zhang Liping, Independent Director
Shang Chuang, Director
Jianyu Yang, Chairman, CEO, Chairman of Compensation Committee and Member of Investment Committee
Boxun Zhang, Independent Director
Jing Zhang, Chief Administrative Officer
Weibo Yin, Independent Director and Member of Audit Committee
William Zima, IR Contact Officer
Jigang Sun, Chief Investment Officer and Chairman of Investment Committee
Yue Yu, Director
Sui Yan, Director
Zheng Cheng, President, Director and Member of Investment Committee
Qing Pan, Director
Elaine Zong, Independent Director
Yongjun Li, Independent Director
Fu Xiao, Chief Operating Officer
Yaw Yap, CFO and Member of Investment Committee
Ting Lee, Independent Non-Executive Director
Liping Zhang, Independent Director
Tian Ji, Independent Director
Zhe Yin, Independent Director

Concord Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Concord Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Concord Medical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Concord Medical's short interest history, or implied volatility extrapolated from Concord Medical options trading.
When determining whether Concord Medical Services is a strong investment it is important to analyze Concord Medical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Concord Medical's future performance. For an informed investment choice regarding Concord Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Concord Medical Services. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.
Note that the Concord Medical Services information on this page should be used as a complementary analysis to other Concord Medical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..

Complementary Tools for Concord Stock analysis

When running Concord Medical's price analysis, check to measure Concord Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Concord Medical is operating at the current time. Most of Concord Medical's value examination focuses on studying past and present price action to predict the probability of Concord Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Concord Medical's price. Additionally, you may evaluate how the addition of Concord Medical to your portfolios can decrease your overall portfolio volatility.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Equity Valuation
Check real value of public entities based on technical and fundamental data
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Is Concord Medical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Concord Medical. If investors know Concord will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Concord Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.94)
Revenue Per Share
12.302
Quarterly Revenue Growth
(0.23)
Return On Assets
(0.05)
Return On Equity
(0.28)
The market value of Concord Medical Services is measured differently than its book value, which is the value of Concord that is recorded on the company's balance sheet. Investors also form their own opinion of Concord Medical's value that differs from its market value or its book value, called intrinsic value, which is Concord Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Concord Medical's market value can be influenced by many factors that don't directly affect Concord Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Concord Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Concord Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Concord Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.